Literature DB >> 16523360

Predictors of regional nodal disease in patients with thin melanomas.

Giorgos C Karakousis1, Phyllis A Gimotty, Jeffrey D Botbyl, Susan B Kesmodel, David E Elder, Rosalie Elenitsas, Michael E Ming, DuPont Guerry, Douglas L Fraker, Brian J Czerniecki, Francis R Spitz.   

Abstract

BACKGROUND: Most melanoma patients present with thin (<or=1.0 mm) lesions. Indications for sentinel lymph node (SLN) biopsy are not well defined for this group. Previously, we reported an association between mitotic rate (MR) and SLN positivity in these patients. The study was limited by a relatively small sample size and low statistical power. In this study, we evaluated a large population of patients with thin melanoma from the pre-SLN era to identify predictors of regional nodal disease (RND) that may serve as a surrogate for SLN positivity.
METHODS: Eight hundred eighty-two patients evaluated between 1972 and 1991 were included in the study. Univariate and multivariate regression analyses were performed by using clinical and histological data to identify factors associated with RND. A multivariate logistic regression model was developed and applied to the previously reported group of patients with thin melanomas who underwent SLN biopsy between 1996 and 2004 for validation.
RESULTS: Thirty-eight patients (4.3%) had evidence of RND. In the multivariate analysis, a MR>0, vertical growth phase (VGP), male sex, and ulceration were statistically significant predictors of RND. Patients at the highest risk according to a classification tree analysis (VGP and MR>0) had an RND rate of 11.9%. The regression model developed predicted well the SLN status in the validation sample.
CONCLUSIONS: Investigation of a large pre-SLN population identified MR>0, ulceration, VGP, and male sex as independently predictive of RND in patients with thin melanomas. These factors may help to identify subgroups of these patients that have clinically significant risks of SLN positivity.

Entities:  

Mesh:

Year:  2006        PMID: 16523360     DOI: 10.1245/ASO.2006.05.011

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

Review 1.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

2.  Using global gene expression to discriminate thin melanomas with poor outcomes.

Authors:  Zachary Hothem; Andrew Bayci; Bryan J Thibodeau; Billie E Ketelsen; Laura E Fortier; Alison F Uzieblo; Diane Cosner; Kristin Totoraitis; Richard D Keidan; George D Wilson
Journal:  Mol Cell Oncol       Date:  2016-11-08

3.  Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.

Authors:  Sumeet Thareja; Jonathan S Zager; Divya Sadhwani; Shalini Thareja; Ren Chen; Suroosh Marzban; Drazen M Jukic; Lewis F Glass; Jane Messina
Journal:  Am J Dermatopathol       Date:  2014-01       Impact factor: 1.533

4.  Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.

Authors:  Edmund K Bartlett; Phyllis A Gimotty; Andrew J Sinnamon; Heather Wachtel; Robert E Roses; Lynn Schuchter; Xiaowei Xu; David E Elder; Michael Ming; Rosalie Elenitsas; DuPont Guerry; Rachel R Kelz; Brian J Czerniecki; Douglas L Fraker; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2013-10-12       Impact factor: 5.344

5.  Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Authors:  Chelsea Isom; Lee Wheless; Mary A Hooks; Rondi M Kauffmann
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

6.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

Review 7.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 8.  Melanoma in pediatric, adolescent, and young adult patients.

Authors:  John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

9.  Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Authors:  Alexander Meves; Ekaterina Nikolova; Joel B Heim; Edwin J Squirewell; Mark A Cappel; Mark R Pittelkow; Clark C Otley; Nille Behrendt; Ditte M Saunte; Jorgen Lock-Andersen; Louis A Schenck; Amy L Weaver; Vera J Suman
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

10.  Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.

Authors:  Edmund K Bartlett; Madalyn G Peters; Anne Blair; Mark S Etherington; David E Elder; Xiaowei G Xu; DuPont Guerry; Michael E Ming; Douglas L Fraker; Brian J Czerniecki; Phyllis A Gimotty; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.